PROCEPT BioRobotics Corporation $PRCT Holdings Trimmed by SG Americas Securities LLC

SG Americas Securities LLC reduced its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 60.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,716 shares of the company’s stock after selling 50,578 shares during the period. SG Americas Securities LLC owned approximately 0.06% of PROCEPT BioRobotics worth $843,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in shares of PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock worth $1,101,000 after purchasing an additional 1,286 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in PROCEPT BioRobotics by 9.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after buying an additional 13,767 shares in the last quarter. Intech Investment Management LLC boosted its holdings in PROCEPT BioRobotics by 54.4% during the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock worth $1,654,000 after buying an additional 10,002 shares in the last quarter. Prudential Financial Inc. grew its position in PROCEPT BioRobotics by 100.4% in the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock worth $393,000 after buying an additional 3,415 shares during the last quarter. Finally, State Street Corp grew its position in PROCEPT BioRobotics by 6.9% in the second quarter. State Street Corp now owns 1,269,110 shares of the company’s stock worth $73,101,000 after buying an additional 81,849 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PRCT shares. Citigroup downgraded PROCEPT BioRobotics to a “hold” rating in a research report on Thursday. Evercore started coverage on PROCEPT BioRobotics in a research report on Wednesday, June 24th. They set an “outperform” rating and a $30.00 target price on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Tuesday, April 21st. Finally, Truist Financial set a $25.00 price target on PROCEPT BioRobotics in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Hold” and an average price target of $40.00.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT opened at $21.03 on Monday. PROCEPT BioRobotics Corporation has a twelve month low of $19.35 and a twelve month high of $62.17. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -11.55 and a beta of 0.87. The firm’s 50 day moving average price is $25.05 and its two-hundred day moving average price is $27.10.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). The business had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $80.52 million. PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. PROCEPT BioRobotics’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.45) EPS. Equities analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.